LLY vs STAA: fair value comparison
Eli Lilly and Company and STAAR Surgical Company · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, LLY currently sits closer to the top of our discount ranking.
| LLY | STAA | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $1,149.36 | $24.34 |
| 12-month range | $862.86–$1,160.00 | $18.04–$29.55 |
| Sector rank | #11 of 113 Healthcare | #13 of 113 Healthcare |
| Quality grade | D | D |
| Leverage | High | Low |
| Margin trend | Expanding | — |
| Revenue growth | High | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: LLY fair value analysis · STAA fair value analysis